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Abstract
Objective
Patient-reported outcomes (PROs) are aspects of a patient’s health status and are considered
important for stimulating patient-centered care. Current outcome measures in clinical care for
patients with aneurysmal subarachnoid hemorrhage (aSAH) are insufficient to capture PROs.
In this systematic review, we aimed to summarize the evidence regarding the quality of patient-
reported outcome measures (PROMs) in aSAH patients.
Methods
We performed a systematic review of the literature published from inception until October 29,
2018, in PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE. Eligible
studies had to evaluate measurement properties and capture PROs in aSAH patients. The
quality of the studies and measurement properties were assessed using the consensus-based
standards for the selection of health status measurement instruments (COSMIN) checklist.
The review protocol was registered with PROSPERO (CRD42018058566).
Results
We identified 9 articles that reported the assessment of 7 different disease-specific and generic
PROMs used for aSAH patients, including 5 that focused on the Stroke-Specific Quality of Life
Scale (SS-QoL). The methodologic quality of the validation processes used was generally
doubtful. None of the PROMs complied with current standards for content validity.
Conclusions
Due to the low quality of evidence for the measurement properties, the evidence base for
selecting a suitable PROM for use with aSAH patients is insufficient. Given the specific long-
term consequences of aSAH, we consider a disease-specific PROM the most appropriate, with
SS-QoL the most suitable PROM currently available.
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Improvements in treatment strategies in aneurysmal sub-
arachnoid hemorrhage (aSAH) led to a reduction in mortality
over the last 30 years,1,2 meaning that the functional outcome
and quality of life of patients with aSAH is becoming in-
creasingly important.1,2 Approximately half of patients report
persistent problems with memory, mood, or neuro-
psychological function.3–5 These cognitive deficits often go
undetected by gross neurologic measures such as the Glasgow
Outcome Scale and the modified Rankin Scale (mRS), but
can be measured using patient-reported outcome measures
(PROMs).4 PROMs measure patient-reported outcomes
(PROs) and reflect the patient’s view of his or her own health
status. They are important for improving patient-centered
health care and managing the follow-up care of patients.6
Although they could be valuable for measuring outcomes that
are not represented in clinical outcomemeasures, PROMs are
seldom used in research involving patients with aSAH.7,8
In this systematic review, we provide an overview of the
available PROMs used in patients with aSAH and review their
validity and reliability. This provides an evidence base for the
future selection of PROMs in aSAH research and clinical
practice, enabling the most effective detection of PROs for
patients with aSAH.
Methods
Search strategy
The review protocol was registered in the International Pro-
spective Register of Systematic Reviews (PROSPERO) of
systematic review protocols (CRD42018058566).9 We per-
formed a systematic search of the literature published from
inception until October 29, 2018, in PubMed, the Cochrane
Central Register of Controlled Trials, and EMBASE. This was
done using a 2-step approach: first, a systematic search of the
literature was performed from inception until August 15,
2017, and second, the search results were updated monthly to
add any potential new studies to the selection. An in-
dependent and experienced librarian contributed to the
search strategy. To identify studies concerning the measure-
ment properties of PROMs, we searched for validation studies
using the keywords “aneurysmal subarachnoid hemorrhage”
and “patient-reported outcomes.” For the latter, we applied
the PROM search filter developed in February 2010 by The
PROMGroupOxford at the University of Oxford.10 The filter
was adjusted and expanded to improve the sensitivity of the
search strategy for our target group. In addition, we applied
the sensitive search filter developed by Terwee et al.11 to
identify studies on measurement properties. For the detailed
search string used in PubMed, see table 1. The search string
was adjusted for use in the other databases. Finally, we per-
formed a reference search of the included full-text articles to
identify other relevant studies.
Selection criteria
Studies were eligible for inclusion if they considered the
measurement properties of PROMs in patients with aSAH.
The aim of the PROM should be to capture the general
aspects of health status, aSAH-related quality of life, or the
symptoms associated with aSAH. The PROM needed to have
been named to enable its identification. Studies were included
if the article was in English, the full text was available, and the
results for patients with aSAHwere presented separately from
any other study population. Editorials and studies concerning
children <18 years of age or nonhumans were excluded.
Data collection and analysis
Selection of studies
Duplicate articles were automatically removed using EndNote
X8. Two researchers (E.N.-J. and R.H.M.A.B.) independently
reviewed the titles and subsequently the abstracts of the
articles. For the included articles, full-text versions were
obtained and independently evaluated by the same
researchers. In case of disagreement during this process,
a third reviewer (P.J.v.d.W.) was asked to adjudicate.
Data analysis
The studies were analyzed in the 3-step procedure described
below.
COSMIN step 1: Quality assessment of the studies
The assessment of the methodologic quality of the included
studies was based on the updated consensus‐based standards
for the selection of health measurement instruments
(COSMIN).12–14 This involves a 3-step appraisal of the
quality of a PROM: (1) the assessment of the content validity;
(2) the appraisal of the internal structure of the questionnaire;
and (3) the evaluation of the remaining measurement prop-
erties (i.e., reliability, measurement error, criterion validity,
and hypotheses testing for construct validity and re-
sponsiveness). These steps are allocated in 10 boxes in the
COSMIN checklist, each with 3–35 items concerning the
methodologic standards for each measurement property.
Each item was independently assessed by 2 researchers (E.N.-
J. and P.J.v.d.W.) using a 4-point rating scale (very good,
adequate, doubtful, or inadequate). Finally, an overall score of
Glossary
aSAH = aneurysmal subarachnoid hemorrhage; EQ-5D = EuroQol 5D; HUI = Health Utility Index; mRS = modified Rankin
Scale; PRO = patient-reported outcome; PROM = patient-reported outcome measure; QOLIBRI-OS = Quality of Life after
Brain Injury overall scale; SAHOT = Subarachnoid Haemorrhage Outcome Tool; SS-QoL = Stroke-Specific Quality of Life
scale.
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Table 1 PubMed search strategy
Step Search terms
No. of studies in
PubMed
1 “Subarachnoid hemorrhage”[MeSH: noexp] 18,588
2 “Intracranial aneurysm”[MeSH] or intracranial aneurysm[tiab] or intracranial aneurysms
[tiab] or brain aneurysms[tiab] or brain aneurysm[tiab] or cerebral aneurysm[tiab] or
cerebral aneurysms[tiab]
27,877
3 “Rupture, spontaneous”[MeSH] or ruptur*[tiab] 117,188
4 Step 2 and step 3 8,527
5 Subarachnoid haemorrhage[tiab] or (subarachnoid[tiab] and hemorrhage[tiab]) or
subarachnoid hemorrhage[tiab] or subarachnoid haemorrhages[tiab] or subarachnoid
hemorrhages[tiab] or sah[tiab] or sahs[tiab] or asah[tiab] or subarachnoid hematoma[tiab]
or subarachnoid bleeding[tiab] or subarachnoid bleed[tiab]
24,472
6 Step 1 or step 4 or step 5 33,127
7 “Quality of life”[MeSH] 150,254
8 “Patient reported outcome measures”[MeSH] 555
9 “Patient outcome assessment"[MeSH:noexp] 3,052
10 “Recovery of function”[MeSH] 40,897
11 “Health care surveys”[MeSH] 29,298
12 “Self report”[MeSH] 18,578
13 “Surveys and questionnaires”[MeSH:noexp] 372,886
14 Step 7 or step 8 or step 9 or step 10 or step 11 or step 12 or step 13 553,425
15 Recovery of function[tiab] or patient outcome assessment[tiab] or patient outcome
assessments[tiab] or patient-centered outcomes[tiab] or patient-centered outcome[tiab]
or patient centered outcome[tiab] or patient centered outcomes[tiab] or patient reported
outcomes[tiab] or patient reported outcome[tiab] or quality of life[tw] or PROM[tiab] or Qol
[tiab] or hrqol[tiab] or HRQL[tiab] or proms[tiab] or questionnaire[tiab] or questionnaires
[tiab] or scale[tiab] or scales[tiab] or health index*[tiab] or health indices[tiab] or health
status[tw] or health profile*[tiab] or HRPRO[tiab] or HR-PRO[tiab] or life quality[tw] or QL
[tiab]
1,219,700
16 (patient[tiab] or self[tiab] or carer[tiab] or proxy[tiab]) and (report[tiab] or reported[tiab] or
reporting[tiab] or rated[tiab] or rating[tiab] or ratings[tiab] or based[tiab] or assessed[tiab]
or assessment[tiab] or assessments[tiab])
1,131,726
17 (disability[tiab] or function[tiab] or functional[tiab] or functions[tiab] or subjective[tiab] or
utility[tiab] or utilities[tiab] or wellbeing[tiab] or well being[tiab]) and (index[tiab] or indices
[tiab] or measure[tiab] or measures[tiab] or profile[tiab] or profiles[tiab] or score[tiab] or
scores[tiab] or status[tiab])
621,602
18 Step 14 or step 15 or step 16 or step 17 2,694,952
19 “Psychometrics”[MeSH] 63,854
20 “Outcome assessment (health care)”[MeSH] 879,542
21 “Observer variation”[MeSH] 37,514
22 “Health status indicators”[MeSH] 237,135
23 “Reproducibility of results”[MeSH] 338,085
24 “Discriminant analysis”[MeSH] 8,987
25 “Factor analysis, statistical”[MeSH] 24,018
26 “Minimal clinically important difference”[MeSH] 19
27 Step 19 or step 20 or step 21 or step 22 or step 23 or step 24 or step 25 or step 26 1,439,025
Continued
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a measurement property was obtained by taking the lowest
score for any of the items in that property.12–15
COSMIN step 2: Quality assessment of the
measurement properties
The definitions used for the measurement properties are
based on the consensus on taxonomy, terminology, and def-
initions reached by the COSMIN panel. The COSMIN cri-
teria were used to assess whether the results of the
measurement properties were sufficient, insufficient, or in-
determinate (table 2).13,15,16 We reviewed the measurement
properties in duplicate (by E.N.-J. and P.J.v.d.W.), and in cases
of initial doubt in the final rating, agreement was reached by
debate between the 2 reviewers. For the hypotheses testing
for construct validity and responsiveness to be considered
sufficient, the result should be in accordance with the hy-
potheses. In cases where no hypotheses were provided in the
article, the review team formulated hypotheses themselves
(table 3).14 Due to the limited studies concerning PROMs in
patients with aSAH, it was not possible to deduce a conclusion
on the quality of measurement properties by statistically
pooling the results; therefore, we report the best evidence
synthesis per measurement property separately. Finally, since
there are no quality criteria for interpretability, we present the
data in the text.
COSMIN step 3: Assessment of the level of the evidence
The quality of the evidence for each PROM was based on the
number and quality of the studies using this approach, and
summarized for each measurement property based on
Table 1 PubMed search strategy (continued)
Step Search terms
No. of studies in
PubMed
28 Instrumentation[sh] or methods[sh] or validation studies[pt] or comparative study[pt] or
psychometr*[tiab] or clinimetr*[tw] or clinometr*[tw] or outcome assessment[tiab] or
outcome measure*[tw] or observer variation[tiab] or reproducib*[tiab] or reliab*[tiab] or
unreliab*[tiab] or valid*[tiab] or coefficient[tiab] or co-efficient[tiab] or homogeneity[tiab]
or homogeneous[tiab] or “internal consistency”[tiab] or agreement[tiab] or precision[tiab]
or imprecision[tiab] or “precise values”[tiab] or test-retest[tiab] or stability[tiab] or
interrater[tiab] or inter-rater[tiab] or intrarater[tiab] or intra-rater[tiab] or intertester[tiab]
or inter-tester[tiab] or intratester[tiab] or intra-tester[tiab] or interobserver[tiab] or inter-
observer[tiab] or intraobserver[tiab] or intra-observer[tiab] or intertechnician[tiab] or
inter-technician[tiab] or intratechnician[tiab] or intra-technician[tiab] or interexaminer
[tiab] or inter-examiner[tiab] or intraexaminer[tiab] or intra-examiner[tiab] or interassay
[tiab] or inter-assay[tiab] or intraassay[tiab] or intra-assay[tiab] or interindividual[tiab] or
inter-individual[tiab] or intraindividual[tiab] or intra-individual[tiab] or interparticipant
[tiab] or inter-participant[tiab] or intraparticipant[tiab] or intra-participant[tiab] or kappa
[tiab] or kappa’s[tiab] or kappas[tiab] or repeatab*[tiab] or generaliza*[tiab] or generalisa*
[tiab] or concordance[tiab] or discriminative[tiab] or “known group”[tiab] or factor analysis
[tiab] or factor analyses[tiab] or dimension*[tiab] or subscale*[tiab] or sub-scale*[tiab] or
item discriminant[tiab] or interscale correlation*[tiab] or inter scale correlation*[tiab] or
error[tiab] or errors[tiab] or “individual variability”[tiab] or “standard error of
measurement”[tiab] or sensitiv*[tiab] or responsive*[tiab] or meaningful change[tiab] or
“ceiling effect”[tiab] or “floor effect"[tiab] or “item response model”[tiab] or IRT[tiab] or
Rasch[tiab] or “differential item functioning”[tiab] or DIF[tiab] or “computer adaptive
testing”[tiab] or “item bank"[tiab] or “cross-cultural equivalence”[tiab]
7,456,435
29 Cronbach*[tiab] and (alpha[tiab] or alphas[tiab]) 17,257
30 Item[tiab] and (correlation*[tiab] or selection*[tiab] or reduction*[tiab]) 16,921
31 Test[tiab] and (retest[tiab] or re-test[tiab] 22,240
32 Reliab*[tiab] and (test[tiab] or (retest[tiab] or re-test)) 73,165
33 (replicab*[tiab] or repeated[tiab]) and (measure[tiab] ormeasures[tiab] or findings[tiab] or
result[tiab] or results[tiab] or test[tiab] or tests[tiab])
165,106
34 Intraclass[tiab] and correlation*[tiab] 18,476
35 Multitrait[tiab] and scaling[tiab] and (analysis[tiab] or analyses[tiab]) 134
36 Variability[tiab] and (analysis[tiab] or values[tiab]) 81,461
37 Uncertainty[tiab] and (measurement[tiab] or measuring[tiab]) 6,239
38 (minimal[tiab] or minimally[tiab] or clinical[tiab] or clinically[tiab]) and (important[tiab] or
significant[tiab] or detectable[tiab]) and (change[tiab] or difference[tiab])
186,806
39 Small*[tiab] and (real[tiab] or detectable[tiab]) and (change[tiab] or difference[tiab]) 6,029
40 Step 27 or step 28 or step 29 or step 30 or step 31 or step 32 or step 33 or step 34 or step 35
or step 36 or step 37 or step 38 or step 39
8,189,416
41 Step 40 and step 18 and step 6 3,814
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Table 2 Quality criteria for measurement properties
Domain Measurement property
Aspect of
a measurement
property Definition Rating Quality criteria
Reliability The degree to which the measurement is free from
measurement error
Internal consistency The degree of interrelatedness among the items + At least low evidenceb for sufficient structural validityc and
Cronbach alpha(s) ≥0.70 for each unidimensional scale or
subscaled
? Criteria for “At least low evidenceb for sufficient structural
validityc” not met
− At least low evidenceb for sufficient structural validityc and
Cronbach alpha(s) <0.70 for each unidimensional scale or
subscaled
Reliability The proportion of the total variance in the
measurements which is due to “true”a differences
between patients
+ ICC or weighted kappa ≥0.70
? ICC or weighted kappa not reported
− ICC or weighted kappa <0.70
Measurement error The systematic and randomerror of a patient’s score,
i.e., not attributed to true changes in the construct to
be measured
+ SDC or LoA <MICc
? MIC not defined
− SDC or LoA > MICc
Validity The degree to which a PROM measures the
construct(s) it purports to measure
Content validity The degree to which the content of a PROM is an
adequate reflection of the construct to be measured
Definitions according to a separate rating system and not
included in this supplement17
Face validity The degree to which (the items of) a PROM indeed
look as though they are an adequate reflection of the
construct to be measured
Construct validity The degree to which the scores of a PROM are
consistent with hypotheses (e.g., with regard to
internal relationships, relationships to scores of
other instruments, or differences between relevant
groups) based on the assumption that the PROM
validly measures the construct to be measured
Continued
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Table 2 Quality criteria for measurement properties (continued)
Domain Measurement property
Aspect of
a measurement
property Definition Rating Quality criteria
Structural validity The degree to which the scores of a PROM are an
adequate reflection of the dimensionality of the
construct to be measured
+ CTT:
CFA: CFI or TLI or comparable measure >0.95 or RMSEA
<0.06 or SRMR <0.08e
IRT/Rasch:
No violation of unidimensionalityf: CFI or TLI or
comparablemeasure >0.95 or RMSEA <0.06 or SRMR <0.08
and
no violation of local independence: residual correlations
among the items after controlling for the dominant factor
<0.20 OR Q3s <0.37
and
no violation of monotonicity: adequate looking graphs or
item scalability >0.30
and
adequate model fit:
IRT: χ2 >0.01
Rasch: infit and outfit mean squares ≥0.5 and ≤1.5 or Z
standardized values >−2 and <2
? CTT: Not all information for “+” reported
IRT/Rasch: Model fit not reported
− Criteria for “+” not met
Hypothesis testing for
construct validity
Thedegree towhich the scores of a PROMare consistent
with hypotheses based on the assumption that the
PROM validly measures the construct to be measured
+ The result is in accordance with the hypothesisg
? No hypothesis defined (by the review team)
− The result is not in accordance with the hypothesisg
Cross-cultural validity/
measurement
invariance
The degree to which the performance of the items on
a translated or culturally adapted PROM are an
adequate reflection of the performance of the items
of the original version of the PROM
+ No important differences found between group factors
(such as age, sex, language) in multiple group factor
analysis or no important DIF for group factors (McFadden
R2 <0.02)
? No multiple group factor analysis or DIF analysis
performed
− Important differences between group factors or DIF was
found
Criterion validity The degree to which the scores of a PROM are an
adequate reflection of a gold standard
+ Correlation with gold standard ≥0.70 or AUC ≥0.70
? Not all information for “+” reported
− Correlation with gold standard <0.70 or AUC <0.70
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Table 2 Quality criteria for measurement properties (continued)
Domain Measurement property
Aspect of
a measurement
property Definition Rating Quality criteria
Responsiveness The ability of a PROM to detect change over time in
the construct to be measured
Responsiveness The ability of a PROM to detect change over time in
the construct to be measured
+ The result is in accordance with the hypothesisg or AUC
≥0.70
? No hypothesis defined (by the review team)
− The result is not in accordance with the hypothesisg or AUC
<0.70
Interpretability Interpretability is the degree to which one can assign
qualitative meaning—i.e., clinical or commonly
understood connotations—to a PROM’s quantitative
scores or change in scores
Abbreviations: AUC = area under the curve; CFA = confirmatory factor analysis; CFI = comparative fit index; CTT = classical test theory; DIF = differential item functioning; ICC = intraclass correlation coefficient; IRT = item
response theory; LoA = limits of agreement; MIC =minimal important change; PROM = patient-reported outcomemeasure; RMSEA = root mean square error of approximation; SRMR = standardized rootmean residuals; TLI =
Tucker-Lewis index.
+ = Sufficient; ? = indeterminate; − = insufficient.
a Theword “true”must be seen in the context of the CTT, which states that any observation comprises 2 components: a true score and error associated with the observation. “True” is the average score that would be obtained if
the scale were given an infinite number of times. It refers only to the consistency of the score, and not to its accuracy.
b As defined by grading the evidence according to the GRADE approach.
c This evidence may come from different studies.
d The criteria “Cronbach α<0.95” was deleted, as this is relevant in the development phase of a PROM and not when evaluating an existing PROM.
e To rate the quality of the summary score, the factor structures should be equal across studies.
f Unidimensionality refers to a factor analysis per subscale, while structural validity refers to a factor analysis of a (multidimensional) PROM.
g The results of all studies should be taken together and it should then be decided if 75% of the results are in accordance with the hypotheses.
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a modification of the GRADE methodology as outlined in the
COSMIN guidelines.16 This methodology considers the ini-
tial level of evidence to be high, with subsequent downgrading
based on the scores for 4 criteria: risk of bias, inconsistencies,
imprecision, and indirectness. This results in a high, moder-
ate, low, or very low quality score for the evidence. To eval-
uate the measurement properties of PROM development and
content validity, the overall level of evidence was based on the
recently updated COSMIN recommendations.17
Data availability
All data included in this review are available in the articles
indicated in table 4. Our search strategy for PubMed is shown
in table 1. The predefined hypotheses of the review team are
Table 3 Hypotheses about correlations as formulated by the review team
The Subarachnoid Haemorrhage Outcome Tool (SAHOT)
Hypotheses testing:
The authors formulated their own hypotheses.
Responsiveness:
mRS: we expect the effect size of the SAHOT to be higher than the effect size of the mRS.
Glasgow Outcome Scale Extended: we expect the effect size of the SAHOT to be higher than the effect size of the mRS.
The Stroke-Specific Quality of Life Scale (SS-QoL)
Hypotheses testing:
SF-36: we expect a low correlation with the physical subscale of the SS-QoL, a moderate correlation with the psychosocial subscale of the SS-QoL, and
a moderate correlation with the total score of the SS-QoL.
mRS: we expect a moderate correlation with the physical subscale of the SS-QoL, a low correlation with the psychosocial subscale of the SS-QoL, and
a low–moderate correlation with the total score of the SS-QoL.
Chinese Lawton Instrumental Activity of Daily Living scale: we expect a moderate correlation with the physical subscale of the SS-QoL, a moderate
correlation with the psychosocial subscale of the SS-QoL, and a moderate correlation with the total score of the SS-QoL.
Geriatric Depression Scale: we expect a low correlationwith the physical subscale of the SS-QoL, amoderate correlationwith the psychosocial subscale of
the SS-QoL, and a low-moderate correlation with the total score of the SS-QoL.
Cognitive Failures Questionnaire: we expect a low correlation with the physical subscale of the SS-QoL, a moderate correlation with the psychosocial
subscale of the SS-QoL, and a low correlation with the total score of the SS-QoL.
Life Satisfaction questionnaire–9: we expect a low–moderate correlation with the physical subscale of the SS-QoL, a low–moderate correlation with the
psychosocial subscale of the SS-QoL, and a low–moderate correlation with the total score of the SS-QoL.
Hospital Anxiety andDepression Scale: we expect a low correlationwith the physical subscale of the SS-QoL, amoderate correlationwith the psychosocial
subscale of the SS-QoL, and a low–moderate correlation with the total score of the SS-QoL.
Glasgow Outcome Scale: we expect a moderate correlation with the physical subscale of the SS-QoL, a low correlation with the psychosocial subscale of
the SS-QoL, and a low-moderate correlation with the total score of the SS-QoL.
Responsiveness:
SF-36: we expect a moderate correlation with the total score of the SS-QoL.
The short version of the SS-QoL
Hypotheses testing:
SF-36: we expect a low correlation with the physical subscale of the SS-QoL-sv, a moderate correlation with the psychosocial subscale of the SS-QoL-sv,
and a moderate correlation with the total score of the SS-QoL-sv.
mRS: we expect amoderate correlationwith the physical subscale of the SS-QoL-sv, a low correlationwith the psychosocial subscale of the SS-QoL-sv, and
a low–moderate correlation with the total score of the SS-QoL-sv.
Chinese Lawton Instrumental Activity of Daily Living scale: we expect a moderate correlation with the physical subscale of the SS-QoL-sv, a moderate
correlation with the psychosocial subscale of the SS-QoL-sv, and a moderate correlation with the total score of the SS-QoL-sv.
Geriatric Depression Scale: we expect a low correlation with the physical subscale of the SS-QoL-sv, a moderate correlation with the psychosocial
subscale of the SS-QoL-sv, and a low–moderate correlation with the total score of the SS-QoL-sv.
Montreal Cognitive Assessment: we expect a low correlation with the physical subscale of the SS-QoL-sv, a moderate correlation with the psychosocial
subscale of the SS-QoL-sv, and a low correlation with the total score of the SS-QoL-sv.
Abbreviations: mRS = modified Rankin Scale; SF-36 = Short Form–36.
Definitions: 0.0–0.2 very low correlation, 0.2–0.4 low correlation, 0.4–0.6 moderate correlation, >0.6 high correlation.
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available in table 3. The list of excluded studies based on full-
text analysis, including the reason for exclusion, is available on
request by investigators. The extracted data are also available
on request.
Results
Selection of validation studies and PROMs
The search strategy yielded 9,062 articles, of which 6,967 were
unique articles. Reference checks resulted in the identification
of 8 additional articles. One article published after the date of
the initial search was included. After the checks of the titles
and abstracts, 47 articles remained. A thorough evaluation of
the full texts resulted in a total of 9 articles included in this
systematic review.18–26 The details of the selection process are
shown in the figure. The main reasons for the exclusion of
articles were that the questionnaire used in the article was not
a PROM or the results for patients with aSAH were not
presented separately from those of patients with other (vas-
cular) diseases. The 9 included articles assessed 7 different
PROMs: EuroQol 5D (EQ-5D), Health Utility Index (HUI),
mRS, Quality of Life after Brain Injury overall scale
(QOLIBRI-OS), Subarachnoid Haemorrhage Outcome Tool
(SAHOT), Stroke-Specific Quality of Life scale (SS-QoL),
and the short version of the SS-QoL. The SAHOT was the
only identified PROM specifically developed for SAH. The
general characteristics of the studies are presented in table 4
and the characteristics of the PROMs in table 5.
COSMIN step 1: Quality of the included studies
The methodologic quality of the included studies is presented
in table 6 for each questionnaire per measurement property.
No assessment of content validity, measurement error, or
cross-cultural validity was made in any of the studies, nor was
there any reference to previous publications reporting on
these measurement properties for the same study population.
The majority of the properties were rated as “doubtful” or
“inadequate.” Flaws in the design of the study or statistical
methods of the study contributed 5 times to a final score of
“doubtful” and once to an “inadequate” score. These flaws
included a lack of a clear description of the applied statistics,
no detailed information about which study group was in-
cluded in the analysis, or other methodologic shortcomings.
In 4 articles, it was unclear whether the scale or subscale was
unidimensional, resulting in a “doubtful” score. The other
causes of a low overall score on a measurement property were
an insufficient sample size in factor analysis, scarce in-
formation on the measurement properties of the comparator
instruments, the inadequate application of statistics, or an
unspecified time interval between repeated measures. Crite-
rion validity was only assessed for the 2 articles concerning the
short version of the SS-QoL, for which the long version
functioned as the gold standard. No gold standards exist for
the other PROMs. The score was once “very good,” and once
“doubtful,” because variance was not calculated separately for
all domains.
COSMIN steps 2 and 3: Measurement
properties and quality of evidence of
the PROMs
The assessment of the measurement properties and the
quality of evidence is shown in table 7. The evidence for the
measurement properties was scarce due to the small number
of studies using these PROMs in patients with aSAH. In ad-
dition, only minimal evidence was available regarding the
interpretability of the PROMs in the articles, and no formal
Table 4 Characteristics of the included studies in the systematic review
Author Year PROM Population
Total no.
of patients
No. of patients
with SAH
Boosman et al.18 2009 SS-QoL Aneurysmal SAH 141 141
Glick et al.19 1999 EQ-5D HUI Aneurysmal SAH 561 561
Lahiri et al.20 2016 mRS SAH 51 51
Pace et al.26 2018 SAHOT Spontaneous SAH 218 218
Post et al.21 2011 SS-QoL short version Aneurysmal SAH/ischemic
stroke or intracerebral
hemorrhage
345 240
Wong et al.23 2012 SS-QoL Aneurysmal SAH and health
volunteers
104 52
Wong et al.24 2013 SS-QoL short version Aneurysmal SAH 100 100
Wong et al.22 2014 QOLIBRI-OS Aneurysmal SAH 64 64
Wong et al.25 2016 SS-QoL Aneurysmal SAH 56 56
Abbreviations: EQ-5D = EuroQol-5D; HUI = Health Utility Index; mRS = modified Rankin Scale; PROM = patient-reported outcome measure; QOLIBRI-OS =
Quality of Life after Brain Injury, overall scale; SAH = subarachnoid hemorrhage; SAHOT = Subarachnoid Haemorrhage Outcome Tool; SS-QoL = Stroke-
Specific Quality of Life scale.
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information on the feasibility of using each PROM for
patients with aSAH was provided. The details of the assessed
measurement properties of each PROM are outlined sepa-
rately below.
Modified Rankin Scale
The mRS is a global disability scale that has an ordinal 7-point
scale ranging from no residual symptoms (score of 0) to
severely disabled (score of 5) or dead (score of 6).27 The mRS
is an outcome measure that represents mobility and disability
in daily and instrumental activities and living arrangements
rather than cognitive and social functioning.28 The mRS is an
outlier within the included PROMs because it has an in-
corporated outcome of death; therefore, in essence it is not
a PROM. A self-assessed mRS was used in the specific article
included in this study, however, which could therefore be
considered a PROM.
There is very low evidence for sufficient reliability between
2 different methods of mRS assessment used, namely
telephonic assessments using a structured interview and self-
reporting obtained via an online survey. The study showed
a nonlinear distribution between the mRS scores, with
41%–43% of patients in the highest category and 4% of
patients in the lowest category, indicating a significant ceiling
effect.20
Quality of Life after Brain Injury overall scale
The QOLIBRI-OS is a 6-item scale developed to determine
the quality of life in patients after brain injury. It includes the
domains physical condition, cognition, emotions, function in
daily life, personal and social life, and current situation and
future prospects.29,30 The internal consistency measurement
property for the QOLIBRI-OS was rated indeterminate with
a very low quality of evidence. No additional information
about interpretability was provided.
Subarachnoid Haemorrhage Outcome Tool
The SAHOT was recently developed as a disease-specific
PROM for patients with spontaneous SAH.26 The SAHOT
Figure Flow chart of the literature search and selection of relevant articles
PROM = patient-reported outcome measure, SAH = subarachnoid hemorrhage.
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was developed in collaboration with patients with aSAH. It
consists of the domains cognition, general aspects of daily life,
physical function, and behavioral and psychological function.
Based on the COSMIN standards, the quality of the PROM
development process was “inadequate,” since the PROM was
adapted after the cognitive interviews took place and the
adjusted items were not retested. In addition, the available
information about the qualitative methods applied was in-
sufficient. The evidence provided for the PROM de-
velopment, hypothesis testing for construct validity, and
responsiveness was of very low quality, which makes it im-
possible to draw conclusions about those measurement
properties. The low quality of evidence for an indeterminate
rating for structural validity and internal consistency was eli-
cited by the lack of detail regarding the Rasch analysis and the
absence of evidence for the unidimensionality of the scale. We
foresee problems in interpreting the scores, as no direction of
change (better or worse) is incorporated in the answer
options (no change, some change, large or severe change).
Some information about the interpretability is provided;
however, this is partially derived from a simulation of a treat-
ment trial and does not represent real-world data since the
SAHOT has not been implemented in clinical practice yet.
The distribution of the SAHOT has a wide range for each
mRS category and all possible categories are scored. There
were no floor or ceiling effects. The SAHOT comprises 56
items (table 4). The interpretation of the SAHOT is complex
due to the Rasch-based interval analysis, which makes its use
less feasible in daily practice. An ordinal scoring version was
developed to solve this complexity, but its validity should be
evaluated.
Stroke-Specific Quality of Life Scale
The SS-QoL is a disease-specific PROM that was developed
to assess the quality of life in patients after stroke. It contains
49 items and comprises the 12 domains energy, family roles,
language, mobility, personality, self-care, social roles, thinking,
upper extremity use, vision, and work or productivity.31 No
conclusions can be drawn regarding the internal consistency,
structural validity, and reliability of the SS-QoL, since the
overall quality of the evidence is very low. The studies include
a Dutch version and a Chinese version of the SS-QoL. The
principal component analysis revealed 2 components: physi-
cal and psychosocial. In the Dutch version, the physical
component includes the following domains: self-care, mo-
bility, upper extremity function, language, vision, and work.
The psychosocial component includes thinking, family roles,
social roles, personality, mood, and energy. In the Chinese
version, language falls in the psychosocial component and the
family roles and energy domains fall in the physical compo-
nent. There is moderate-quality evidence for sufficient hy-
potheses testing. The responsiveness of the SS-QoL was rated
insufficient, with very low evidence quality. The face validity
was insufficient, since the answer categories did not fit with all
the questions. The distribution of the results showed a ceiling
effect for almost all of the 12 domains, except for thinking and
energy. Almost none of the patients had the lowest possible
score, indicating no floor effects. A ceiling effect of 15% was
Table 5 Characteristics of the included patient-reported outcome measures (PROMs) in the systematic review
Name
Year of
development of
the PROM
(references)
Original
language Domain No. of items
Original target
population
EQ-5D 199032 English Anxiety/depression, global indication of health status,
mobility, pain/discomfort, self-care, usual activities
6 General
population
HUI 199533 English Cognition, emotion, fertility, mobility, pain, self-care,
sensation
7 Childhood
cancer
mRS
structured
interview
195727 English Functional outcome 27 Stroke
QOLIBRI-
OS
201229,30 Dutch, English,
Finnish, French,
German, Italian
Cognition, current situation and future prospects,
emotions, function in daily life, personal and social life,
physical condition
6 Traumatic brain
injury
SAHOT 201826 English Cognition, general aspects of daily life, physical
function, behavioral and psychological function
56 Spontaneous
subarachnoid
haemorrhage
SS-QoL 199931 English Energy, family roles, language, mobility, mood,
personality, self-care, social roles, thinking, upper
extremity use, vision, work/productivity
49 Stroke
SS-QoL
short
version
201121 Dutch, Chinese Energy, family roles, language, mobility, mood,
personality, self-care, social roles, thinking, upper
extremity use, vision, work/productivity
12 Stroke
Abbreviations: EQ-5D = EuroQol-5D; HUI =Health Utility Index;mRS =modified Rankin Scale; QOLIBRI =Quality of Life after Brain Injury overall scale; SAHOT =
Subarachnoid Haemorrhage Outcome Tool; SS-QoL = Stroke-Specific Quality of Life scale.
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Table 6 Methodologic quality assessment of the included studies per measurement property per patient-reported outcome measure (PROM)
Questionnaire, first
author, and year
PROM
development
Content
validity
Structural
validity
Internal
consistency
Cross-cultural validity/
measurement invariance Reliability
Measurement
error
Criterion
validity
Hypotheses testing for
construct validity Responsiveness
mRS-SI
Lahiri 2016 D
QOLIBRI-OS
Wong 2014 D
SAHOT
Pace 2018 IA D D IA D
SS-QoL
Boosman 2010 IA VG D
Wong 2012 IA D IA D
Wong 2016 D
SS-QoL short version
Post 2011 D VG
Wong 2013 D D A
Abbreviations: A = adequate; D = doubtful; EQ-5D = EuroQol-5D; HUI = Health Utility Index; IA = inadequate; mRS-SI = modified Rankin Scale structured interview; QOLIBRI-OS = Quality of Life after Brain Injury overall scale;
SAHOT = Subarachnoid Haemorrhage Outcome Tool; SS-QoL = Stroke-Specific Quality of Life scale; VG = very good.
Only assessed measurement properties are shown.
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found for the physical component as a whole, but not for the
psychosocial component or the total score on the SS-QoL.
With regard to the feasibility of use, the time required for its
completion was not described.
Short version of the SS-QoL
The short version of the SS-QoL was developed since com-
pleting the SS-QoL is time-consuming. It consists of the same
12 domains as the SS-QoL with only one question per do-
main, resulting in a total of 12 items.21 The internal consis-
tency score was “doubtful” for this PROM, as no factor
analysis was applied. This means that the evidence is of a very
low quality and no conclusions can be drawn for the internal
consistency of the short version of the SS-QoL. The quality of
the evidence regarding a sufficient criterion validity of this
PROM is high, with the long version considered the gold
standard. As in the long version, there is moderate quality of
evidence for the sufficient hypothesis testing for construct
validity in the short SS-QoL. As with the long version, the face
validity of the short SS-QoL was insufficient due to the mis-
match of the answer categories with some questions.
Generic PROMs
The EQ-5D is a generic PROM comprising 5 domains: mo-
bility, self-care, usual activities, pain or discomfort, and anxiety
or depression. The last question is a visual analogue scale to
determine a patient’s self-rated general health.32 The HUI is
health status classification system and consists of the domains
sensation, mobility, emotions, cognition, self-care, pain, and
fertility.33 For the generic EQ-5D and HUI, the articles
Table 7 Quality of assessedmeasurement properties per patient-reported outcomemeasure (PROM) per study and the
quality of the evidence per measurement properties
Questionnaire, first
author, and year
PROM
development
Structural
validity
Internal
consistency Reliability
Criterion
validity
Hypotheses
testing Responsiveness
mRS-SI
Lahiri 2016 +
Overall rating +
Quality of evidence Very low
QOLIBRI-OS
Wong 2014 ?
Overall rating ?
Quality of evidence Very low
SAHOT
Pace 2018 ± ? ? + −
Overall rating ± ? ? + −
Quality of evidence Very low Low Low Very low Very low
SS-QoL
Boosman 2010 + ? NA + NA
Wong 2012 + ? ? + NA
Wong 2016 NA NA NA NA −
Overall rating + ? ? + −
Quality of evidence Very low Very low Very low Moderate Very low
SS-Qol short version
Post 2011 ? + NA
Wong 2013 ? + +
Overall rating ? + +
Quality of evidence Very low High Moderate
Abbreviations: + = Sufficient; ? = indeterminate; − = insufficient; ± = inconsistent; EQ-5D = EuroQol-5D; HUI = Health Utility Index; mRS-SI = modified Rankin
Scale structured interview; NA = no information available; QOLIBRI-OS = Quality of Life after Brain Injury overall scale; SAHOT = Subarachnoid Haemorrhage
Outcome Tool; SS-QoL = Stroke-Specific Quality of Life scale.
Only assessed measurement properties are shown.
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provided no information about the assessment of the mea-
surement properties when using these measures for patients
with aSAH. Only a little information regarding the in-
terpretability was available. The visual analogue scores for the
EQ-5D instrument were skewed toward higher scores.19
Discussion
In this systematic review, we found limited evidence con-
cerning the assessment of the measurement properties of
PROMs when evaluating the outcomes of patients with
aSAH. The SS-QoL has been evaluated extensively in patients
with aSAH. However, the majority of information regarding
the measurement properties is incomplete and the evidence is
of a very low quality. The SAHOT was the only PROM
specifically developed for patients with aSAH, but the evi-
dence for the measurement properties is of a very low quality.
This means it is impossible to draw conclusions about the
measurement properties of the SAHOT. None of the PROMs
provided evidence for sufficient content validity, which is of
utmost importance when using a PROM in clinical practice or
research. This lack of assessment of content validity means
that all these PROMs might measure items that are not rel-
evant for patients with aSAH, or that items could be inter-
preted in a different way than originally intended. The current
evidence base for selecting a suitable PROM for use with
patients with aSAH is therefore insufficient. This result is
backed by the results of a recent review about the involvement
of patients in the development of PROMs, published in this
journal.34 We did not find any high-quality evidence to sug-
gest that the measurement properties are inherently in-
sufficient, however. Therefore, all identified PROMs have the
potential to be used for patients with aSAH, but their quality
should undergo further assessment. Future research should
focus on the assessment of content validity and measurement
errors to ensure that the PROM is suitable for use in in-
dividual patient care. Given the specific long-term con-
sequences of an aSAH, we consider a disease-specific PROM
to be the most appropriate; therefore, the SS-QoL, in long or
in short version, seems the most suitable PROM for use with
patients with aSAH at this time.
Search strategy and selection of studies
and PROMs
Our systematic review identified a limited number of available
validation studies. To a certain extent this is due to the in-
clusion and exclusion criteria we used. The most important
reason for exclusion was that the results for patients with
aSAH were not described separately from those of patients
with other vascular diseases. An aSAH is a different entity
from an ischemic stroke, hemorrhagic stroke, or unruptured
aneurysm. Patients with aSAH are generally younger than
patients who experience other types of stroke, which results in
the higher interference of symptoms in their societal partici-
pation and social roles.35 Despite this, these vascular diseases
are often combined in validation studies of PROMs and
conclusions are made for the whole group.We explicitly chose
to acknowledge the different disease entities and to focus
solely on patients with aSAH. Our search identified 6,976
unique articles on PROs and aSAH, of which just 9 articles
were included in the final review. The huge reduction of eli-
gible studies in the selection process was caused by the broad
terms we used to cover all relevant PROMs, since no pre-
specified list of known PROMs was available.
COSMIN guidelines
Recently, COSMIN addressed the shortcomings in a former
checklist by publishing the “Risk of Bias” checklist that was
used in this review.14 Despite these improvements, some
limitations can still be identified in this checklist. The detailed
description of comparator instruments is often limited. The
comparator instruments used in the included articles are often
well known and have been validated for use with various
disease entities, but often not for use with patients with aSAH;
however, this does not necessarily mean that the methodo-
logic quality of the study is low. In cases where a widely ac-
cepted questionnaire, such as the Short Form–36 or EQ-5D,
was used as a comparator instrument, we decided to score this
item as “adequate.” In articles using a questionnaire that is not
yet widely accepted, such as the Brain Injury Community
Rehabilitation outcome–39 or the Life Satisfaction ques-
tionnaire, we scored this item as “doubtful.”
Normally, the results of validation studies would be statisti-
cally pooled to estimate an average score for the measurement
properties. Due to the identification of only one validation
study for most PROMs, it was impossible to pool our results.
Even for the SS-QoL, for which more studies were available,
pooling the domains with an “inadequate” quality score would
have resulted in a bias in the pooled results. Other systematic
reviews proved that pooling results is inappropriate when
different language versions of the PROM are included.36,37
This is mainly caused by a nonformalized translation process
or the lack of cross-cultural validation. In our review, a Dutch
version and a Chinese version of the SS-QoL were included.
In all 5 studies concerning the (short) SS-QoL, no assessment
of cross-cultural validation was performed. We therefore de-
cided not to pool the results for the SS-QoL.
Quality of measurement properties
A thorough validation process is important to ensure that the
outcomes of a PROMcan be relied upon for individual patient
care. As mentioned earlier, the evaluation of content validity is
vital for the interpretation of the patient outcomes, while
reliability, which includes measurement error, is also an im-
portant feature. Measurement error is the proportion of the
total variance caused by true differences between patients and
not by a systematic or random error. In addition, in-
terpretability supplies important information about assigning
a qualitative meaning to the scores and teaches us how to
interpret the score of an individual patient using a PROM.
Only after the assessment of these properties can we say that
the PROM properly measures its intended factors and that its
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outcomes can be used to derive clinical meaning.We expected
that the investigated PROMs would at least fulfil these
requirements; however, this review indicates that further re-
search is required to accomplish this.
The studies included in this review often stated that an as-
sessment of a certain measurement property was performed,
when in fact another measurement property was assessed
based on the definitions made by the COSMIN panel.15 For
instance, when criterion validity was mentioned in several
studies, actually hypotheses testing for construct validity was
assessed. In the assessment of hypotheses testing and re-
sponsiveness, hypotheses about the expected correlations
were lacking. This shortage in formulated hypotheses is a well-
known problem when reviewing the measurement properties
of validation studies14,38; therefore, we formulated our own
hypotheses for correlations when they were not reported in
the included studies (table 3). Sometimes, not all of our hy-
potheses were met. In these cases, we discussed whether the
correlation with the related constructs was higher than the
correlation with unrelated constructs. Overall, this resulted in
a sufficient rating for all assessments, except for the re-
sponsiveness of the SAHOT.26 The authors of the article
about the SAHOT formulated their own hypotheses with
regard to construct validity, and these hypotheses were met;
however, we identified some discrepancies in the specified
hypotheses. We thought it remarkable to expect a high cor-
relation between the results of the SAHOT and a question-
naire addressing cognitive and emotional problems, but a low
correlation with a questionnaire measuring psychosocial
functioning. Given that both outcomes are incorporated in
the SAHOT and both are well-known health problems for
patients after an aSAH, we would have expected a moderate
correlation between the results of the SAHOT and both
questionnaires. It may therefore be useful to formulate hy-
potheses for all correlations in a systematic review, regardless
of the hypotheses reported in the studies.
Strengths
This is the first systematic review to evaluate the measurement
properties of PROMs in patients with aSAH. We used all-
embracing search terms that led to a large amount of included
titles, which made the search very sensitive. On this ground,
we expect to have found all important validation studies
concerning PROMs in patients with aSAH. The use of the
recently updated COSMIN checklist and the completion of
this checklist by 2 independent raters is a strength of the
present study. Moreover, in the case of disagreement, we
reached a consensus on a final rating by debate and a thorough
evaluation of the content and criteria. The reporting of our
results is transparent and comprehensive. We illustrate this by
presenting our complete search string and a priori formulated
hypotheses.
Limitations
We slightly deviated from the registered study protocol by
deleting our second search strategy for the use of PROMs in
randomized controlled trials. In 2018, a systematic review was
published that covered our second research question and
provided an extended overview of the different outcome
measures, including PROMs, used in trials.8 We believe that
our decision to report only the first and main search strategy
results in a more easily readable article while still answering
our most important research question.
Second, we used the updated COSMIN “Risk of Bias” checklist
for the assessment of the quality of the included studies. No
research has yet been performed to evaluate the inter-rater
agreement and reliability of this updated checklist. The per-
centage agreement on the original version of the COSMIN
checklist was high on an item level, but the reliability, that is, the
measure that indicates howwell articles can be distinguished from
each other based on the given score, was poor for many items.39
Another limitation is that our methodology for article selec-
tion does not ensure that all PROMs used in literature are
included. Due to the high number of studies, we used an initial
screening of abstracts, which might have led to missed
PROMs that were described in the full-text version of the
article. In addition, evidence concerning aspects of the validity
of a PROM can be deduced from studies in which the vali-
dation of this particular PROM is not the primary objective of
the study. Nevertheless, it is not possible to identify all these
studies with a systematic literature search without restrictions
on the inclusion of PROMs; therefore, we chose not to in-
clude these sorts of articles in our systematic review.
There are limited validation studies concerning the mea-
surement properties of PROMs used in patients with aSAH.
At least half of the information on the measurement proper-
ties is not assessed or the level of evidence is very low. All
PROMs identified in this review have the potential to be used
for patients with aSAH, but lack a thorough evaluation of the
content validity. This means that no conclusions can be drawn
about the validity and reliability of the current PROMs used
for patients with aSAH. Future research should focus on the
assessment of content validity and measurement error to
judge the suitability of a PROM for use in individual patient
care. Given the specific long-term consequences of aSAH, we
consider a disease-specific PROM the most appropriate
choice. Our review suggests that the SS-QoL, in long or in
short version, is the most suitable PROM currently available.
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